OA12021A - Compounds for the treatment of ischemia. - Google Patents

Compounds for the treatment of ischemia. Download PDF

Info

Publication number
OA12021A
OA12021A OA1200200072A OA1200200072A OA12021A OA 12021 A OA12021 A OA 12021A OA 1200200072 A OA1200200072 A OA 1200200072A OA 1200200072 A OA1200200072 A OA 1200200072A OA 12021 A OA12021 A OA 12021A
Authority
OA
OAPI
Prior art keywords
alkyl
compound
chloro
pyrazole
mono
Prior art date
Application number
OA1200200072A
Other languages
English (en)
Inventor
Michael Paul Deninno
Robert William Scott
Hiroko Masamune
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12021A publication Critical patent/OA12021A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
OA1200200072A 1999-09-30 2000-09-22 Compounds for the treatment of ischemia. OA12021A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30

Publications (1)

Publication Number Publication Date
OA12021A true OA12021A (en) 2006-04-19

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200072A OA12021A (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia.

Country Status (41)

Country Link
EP (1) EP1216257B1 (de)
JP (1) JP2003510331A (de)
KR (1) KR100481605B1 (de)
CN (1) CN1374967A (de)
AP (1) AP2002002458A0 (de)
AR (1) AR029887A1 (de)
AT (1) ATE312117T1 (de)
AU (1) AU778185B2 (de)
BG (1) BG106636A (de)
BR (1) BR0014384A (de)
CA (1) CA2386079A1 (de)
CO (1) CO5180581A1 (de)
CR (1) CR6592A (de)
CZ (1) CZ20021020A3 (de)
DE (1) DE60024649D1 (de)
EA (1) EA005422B1 (de)
EC (1) ECSP003682A (de)
EE (1) EE200200172A (de)
GE (1) GEP20043241B (de)
GT (1) GT200000161A (de)
HK (1) HK1049011A1 (de)
HR (1) HRP20020253A2 (de)
HU (1) HUP0202807A3 (de)
IL (1) IL148222A0 (de)
IS (1) IS6286A (de)
MA (1) MA26822A1 (de)
MX (1) MXPA02003308A (de)
MY (1) MY133996A (de)
NO (1) NO20021474L (de)
NZ (1) NZ517177A (de)
OA (1) OA12021A (de)
PA (1) PA8503301A1 (de)
PE (1) PE20010696A1 (de)
PL (1) PL357371A1 (de)
SK (1) SK4182002A3 (de)
TN (1) TNSN00191A1 (de)
TR (1) TR200200843T2 (de)
UA (1) UA73525C2 (de)
WO (1) WO2001023399A1 (de)
YU (1) YU23102A (de)
ZA (1) ZA200202461B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purinderivate zur Behandlung von Ischämie
CN1585634A (zh) * 2001-11-02 2005-02-23 安万特药物公司 包含腺苷a1/a2激动剂和钠-氢离子交换抑制剂的药物组合物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
ES2318129T3 (es) * 2002-04-18 2009-05-01 Cv Therapeutics, Inc. Procedimiento de tratamiento de arritmias quie comprende la administracion de un agonista de adenosina a1 con un betabloqueante.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050101644A1 (en) * 2003-11-10 2005-05-12 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN101132802A (zh) 2004-03-24 2008-02-27 法斯根有限责任公司 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法
EA011097B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
WO2006015830A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
AU2005279208B2 (en) * 2004-08-30 2011-02-24 Janssen Pharmaceutica N.V. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006024628A1 (en) 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン, エルエルシー Mtor阻害剤を使用する強化された治療レジメン
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
CA2872012C (en) 2012-05-08 2017-06-20 Aeromics, Llc New methods
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
EP2968340A4 (de) 2013-03-15 2016-08-10 Intellikine Llc Kombination von kinaseinhibitoren und verwendungen davon
WO2015069961A1 (en) * 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (de) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
ATE206432T1 (de) * 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten

Also Published As

Publication number Publication date
BG106636A (bg) 2003-01-31
CR6592A (es) 2004-02-23
EE200200172A (et) 2003-06-16
MY133996A (en) 2007-11-30
AP2002002458A0 (en) 2002-06-30
JP2003510331A (ja) 2003-03-18
AR029887A1 (es) 2003-07-23
DE60024649D1 (de) 2006-01-12
NO20021474D0 (no) 2002-03-25
CO5180581A1 (es) 2002-07-30
ZA200202461B (en) 2003-05-28
ECSP003682A (es) 2002-04-23
EA200200316A1 (ru) 2002-08-29
WO2001023399A1 (en) 2001-04-05
CZ20021020A3 (cs) 2003-04-16
EA005422B1 (ru) 2005-02-24
PE20010696A1 (es) 2001-07-05
KR100481605B1 (ko) 2005-04-08
HRP20020253A2 (en) 2004-04-30
HK1049011A1 (zh) 2003-04-25
AU7035200A (en) 2001-04-30
BR0014384A (pt) 2002-07-02
CA2386079A1 (en) 2001-04-05
AU778185B2 (en) 2004-11-18
GEP20043241B (en) 2004-05-25
UA73525C2 (en) 2005-08-15
SK4182002A3 (en) 2003-04-01
YU23102A (sh) 2006-01-16
PL357371A1 (en) 2004-07-26
EP1216257B1 (de) 2005-12-07
EP1216257A1 (de) 2002-06-26
CN1374967A (zh) 2002-10-16
NZ517177A (en) 2003-10-31
PA8503301A1 (es) 2003-06-30
HUP0202807A3 (en) 2005-02-28
IL148222A0 (en) 2002-09-12
KR20020034206A (ko) 2002-05-08
ATE312117T1 (de) 2005-12-15
HUP0202807A2 (hu) 2002-12-28
MXPA02003308A (es) 2002-10-04
TNSN00191A1 (fr) 2005-11-10
IS6286A (is) 2002-02-26
MA26822A1 (fr) 2004-12-20
NO20021474L (no) 2002-05-22
TR200200843T2 (tr) 2002-07-22
GT200000161A (es) 2002-03-22

Similar Documents

Publication Publication Date Title
OA12021A (en) Compounds for the treatment of ischemia.
US6803457B1 (en) Compounds for the treatment of ischemia
US20030055021A1 (en) Compounds for the treatment of ischemia
AU739403B2 (en) N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia
ES2211806T3 (es) Derivados beta-carbolina utiles como inhibidores de la fosfodiesterasa.
ES2397947T3 (es) 4-amino-3,5-diciano-2-tiopiridinas sustituidas y su uso
ES2379308T3 (es) Pirrolo[2,3-B]- y pirazolo[3,4-B]piridinas sustituidas como ligandos del receptor de adenosina
US9040516B2 (en) Uracil derivative and use thereof for medical purposes
WO2005012323A2 (en) Compounds useful as a3 adenosine receptor agonists